nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Naloxone—TLR4—Crohn's disease	0.0192	0.889	CrCbGaD
Naltrexone—Cholelithiasis—Mesalazine—Crohn's disease	0.00846	0.0106	CcSEcCtD
Naltrexone—Upset stomach—Mesalazine—Crohn's disease	0.00803	0.0101	CcSEcCtD
Naltrexone—Pharyngolaryngeal pain—Mesalazine—Crohn's disease	0.00779	0.00981	CcSEcCtD
Naltrexone—Abdominal cramps—Mesalazine—Crohn's disease	0.00779	0.00981	CcSEcCtD
Naltrexone—Laryngeal pain—Mesalazine—Crohn's disease	0.00772	0.00972	CcSEcCtD
Naltrexone—Hepatotoxicity—Azathioprine—Crohn's disease	0.00748	0.00942	CcSEcCtD
Naltrexone—Throat sore—Mesalazine—Crohn's disease	0.0073	0.00919	CcSEcCtD
Naltrexone—Oropharyngeal discomfort—Mesalazine—Crohn's disease	0.00723	0.00911	CcSEcCtD
Naltrexone—Rigors—Azathioprine—Crohn's disease	0.00707	0.00891	CcSEcCtD
Naltrexone—Hepatotoxicity—Mesalazine—Crohn's disease	0.00681	0.00858	CcSEcCtD
Naltrexone—Withdrawal symptom—Prednisone—Crohn's disease	0.00678	0.00854	CcSEcCtD
Naltrexone—Withdrawal syndrome—Prednisone—Crohn's disease	0.00666	0.00839	CcSEcCtD
Naltrexone—Rhinorrhoea—Mesalazine—Crohn's disease	0.00649	0.00817	CcSEcCtD
Naltrexone—Gamma-glutamyltransferase increased—Mesalazine—Crohn's disease	0.00639	0.00805	CcSEcCtD
Naltrexone—Delirium—Mesalazine—Crohn's disease	0.00611	0.0077	CcSEcCtD
Naltrexone—Pancreatitis acute—Prednisone—Crohn's disease	0.00603	0.00759	CcSEcCtD
Naltrexone—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.00586	0.00738	CcSEcCtD
Naltrexone—Oropharyngeal pain—Mesalazine—Crohn's disease	0.00578	0.00728	CcSEcCtD
Naltrexone—Drug withdrawal syndrome—Prednisone—Crohn's disease	0.00567	0.00714	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Mesalazine—Crohn's disease	0.00556	0.007	CcSEcCtD
Naltrexone—Colitis—Azathioprine—Crohn's disease	0.00554	0.00698	CcSEcCtD
Naltrexone—Abnormal dreams—Mesalazine—Crohn's disease	0.0052	0.00654	CcSEcCtD
Naltrexone—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00513	0.00646	CcSEcCtD
Naltrexone—Colitis—Mesalazine—Crohn's disease	0.00505	0.00636	CcSEcCtD
Naltrexone—Lymphadenopathy—Mesalazine—Crohn's disease	0.00447	0.00563	CcSEcCtD
Naltrexone—Immune system disorder—Mercaptopurine—Crohn's disease	0.0044	0.00553	CcSEcCtD
Naltrexone—Gastroenteritis—Mesalazine—Crohn's disease	0.00431	0.00542	CcSEcCtD
Naltrexone—Alopecia—Mercaptopurine—Crohn's disease	0.0043	0.00541	CcSEcCtD
Naltrexone—Disorientation—Mesalazine—Crohn's disease	0.00427	0.00537	CcSEcCtD
Naltrexone—Malnutrition—Mercaptopurine—Crohn's disease	0.00424	0.00533	CcSEcCtD
Naltrexone—Libido decreased—Mesalazine—Crohn's disease	0.00412	0.00518	CcSEcCtD
Naltrexone—Increased appetite—Mesalazine—Crohn's disease	0.00406	0.00512	CcSEcCtD
Naltrexone—Atrial fibrillation—Mesalazine—Crohn's disease	0.00403	0.00507	CcSEcCtD
Naltrexone—Thirst—Mesalazine—Crohn's disease	0.00401	0.00505	CcSEcCtD
Naltrexone—Suicidal ideation—Prednisone—Crohn's disease	0.00397	0.005	CcSEcCtD
Naltrexone—Arthritis—Mesalazine—Crohn's disease	0.00393	0.00495	CcSEcCtD
Naltrexone—Lethargy—Mesalazine—Crohn's disease	0.0039	0.00491	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.00382	0.00481	CcSEcCtD
Naltrexone—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.00379	0.00477	CcSEcCtD
Naltrexone—Migraine—Mesalazine—Crohn's disease	0.00376	0.00473	CcSEcCtD
Naltrexone—Face oedema—Mesalazine—Crohn's disease	0.00369	0.00464	CcSEcCtD
Naltrexone—Arthralgia—Mercaptopurine—Crohn's disease	0.00361	0.00454	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00358	0.00451	CcSEcCtD
Naltrexone—Abdominal pain upper—Mesalazine—Crohn's disease	0.00349	0.00439	CcSEcCtD
Naltrexone—Abdominal discomfort—Azathioprine—Crohn's disease	0.00347	0.00437	CcSEcCtD
Naltrexone—Oedema—Mercaptopurine—Crohn's disease	0.00346	0.00435	CcSEcCtD
Naltrexone—Cramp muscle—Mesalazine—Crohn's disease	0.00344	0.00433	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00344	0.00433	CcSEcCtD
Naltrexone—Nasopharyngitis—Mesalazine—Crohn's disease	0.00341	0.0043	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00337	0.00424	CcSEcCtD
Naltrexone—Skin disorder—Mercaptopurine—Crohn's disease	0.00336	0.00423	CcSEcCtD
Naltrexone—Influenza—Mesalazine—Crohn's disease	0.0033	0.00415	CcSEcCtD
Naltrexone—Anorexia—Mercaptopurine—Crohn's disease	0.0033	0.00415	CcSEcCtD
Naltrexone—Pneumonia—Azathioprine—Crohn's disease	0.00325	0.00409	CcSEcCtD
Naltrexone—Delirium—Prednisone—Crohn's disease	0.00324	0.00407	CcSEcCtD
Naltrexone—Infestation NOS—Azathioprine—Crohn's disease	0.00323	0.00407	CcSEcCtD
Naltrexone—Infestation—Azathioprine—Crohn's disease	0.00323	0.00407	CcSEcCtD
Naltrexone—Angina pectoris—Mesalazine—Crohn's disease	0.00321	0.00405	CcSEcCtD
Naltrexone—Bronchitis—Mesalazine—Crohn's disease	0.00317	0.004	CcSEcCtD
Naltrexone—Abdominal discomfort—Mesalazine—Crohn's disease	0.00316	0.00398	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00315	0.00397	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00307	0.00386	CcSEcCtD
Naltrexone—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00305	0.00385	CcSEcCtD
Naltrexone—Decreased appetite—Mercaptopurine—Crohn's disease	0.00301	0.00378	CcSEcCtD
Naltrexone—Weight increased—Mesalazine—Crohn's disease	0.003	0.00378	CcSEcCtD
Naltrexone—Weight decreased—Mesalazine—Crohn's disease	0.00299	0.00376	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00298	0.00376	CcSEcCtD
Naltrexone—Pneumonia—Mesalazine—Crohn's disease	0.00296	0.00373	CcSEcCtD
Naltrexone—Infestation—Mesalazine—Crohn's disease	0.00294	0.0037	CcSEcCtD
Naltrexone—Infestation NOS—Mesalazine—Crohn's disease	0.00294	0.0037	CcSEcCtD
Naltrexone—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00294	0.0037	CcSEcCtD
Naltrexone—Ulcer—Prednisone—Crohn's disease	0.00294	0.0037	CcSEcCtD
Naltrexone—Depression—Mesalazine—Crohn's disease	0.00293	0.00369	CcSEcCtD
Naltrexone—Urinary tract infection—Mesalazine—Crohn's disease	0.00286	0.0036	CcSEcCtD
Naltrexone—Conjunctivitis—Mesalazine—Crohn's disease	0.00286	0.0036	CcSEcCtD
Naltrexone—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00278	0.0035	CcSEcCtD
Naltrexone—Epistaxis—Mesalazine—Crohn's disease	0.00277	0.00349	CcSEcCtD
Naltrexone—Sinusitis—Mesalazine—Crohn's disease	0.00276	0.00348	CcSEcCtD
Naltrexone—Body temperature increased—Mercaptopurine—Crohn's disease	0.00273	0.00344	CcSEcCtD
Naltrexone—Hepatitis—Mesalazine—Crohn's disease	0.00264	0.00333	CcSEcCtD
Naltrexone—Pharyngitis—Mesalazine—Crohn's disease	0.00262	0.0033	CcSEcCtD
Naltrexone—Immune system disorder—Azathioprine—Crohn's disease	0.00262	0.0033	CcSEcCtD
Naltrexone—Mediastinal disorder—Azathioprine—Crohn's disease	0.00261	0.00329	CcSEcCtD
Naltrexone—Chills—Azathioprine—Crohn's disease	0.0026	0.00328	CcSEcCtD
Naltrexone—Connective tissue disorder—Mesalazine—Crohn's disease	0.0026	0.00327	CcSEcCtD
Naltrexone—Alopecia—Azathioprine—Crohn's disease	0.00256	0.00323	CcSEcCtD
Naltrexone—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00255	0.00321	CcSEcCtD
Naltrexone—Eye disorder—Mesalazine—Crohn's disease	0.00247	0.00311	CcSEcCtD
Naltrexone—Tinnitus—Mesalazine—Crohn's disease	0.00246	0.0031	CcSEcCtD
Naltrexone—Cardiac disorder—Mesalazine—Crohn's disease	0.00245	0.00309	CcSEcCtD
Naltrexone—Hyperkinesia—Prednisone—Crohn's disease	0.00243	0.00306	CcSEcCtD
Naltrexone—Naloxone—ALB—Crohn's disease	0.0024	0.111	CrCbGaD
Naltrexone—Angiopathy—Mesalazine—Crohn's disease	0.0024	0.00302	CcSEcCtD
Naltrexone—Euphoric mood—Prednisone—Crohn's disease	0.00239	0.00301	CcSEcCtD
Naltrexone—Immune system disorder—Mesalazine—Crohn's disease	0.00239	0.003	CcSEcCtD
Naltrexone—Mediastinal disorder—Mesalazine—Crohn's disease	0.00238	0.003	CcSEcCtD
Naltrexone—Chills—Mesalazine—Crohn's disease	0.00237	0.00298	CcSEcCtD
Naltrexone—Diarrhoea—Mercaptopurine—Crohn's disease	0.00237	0.00298	CcSEcCtD
Naltrexone—Ill-defined disorder—Azathioprine—Crohn's disease	0.00234	0.00295	CcSEcCtD
Naltrexone—Alopecia—Mesalazine—Crohn's disease	0.00233	0.00294	CcSEcCtD
Naltrexone—Mental disorder—Mesalazine—Crohn's disease	0.00231	0.00291	CcSEcCtD
Naltrexone—Malaise—Azathioprine—Crohn's disease	0.00228	0.00287	CcSEcCtD
Naltrexone—Flatulence—Mesalazine—Crohn's disease	0.00227	0.00285	CcSEcCtD
Naltrexone—Tension—Mesalazine—Crohn's disease	0.00226	0.00284	CcSEcCtD
Naltrexone—Dysgeusia—Mesalazine—Crohn's disease	0.00225	0.00284	CcSEcCtD
Naltrexone—Nervousness—Mesalazine—Crohn's disease	0.00223	0.00281	CcSEcCtD
Naltrexone—Cardiac failure congestive—Prednisone—Crohn's disease	0.00223	0.0028	CcSEcCtD
Naltrexone—Back pain—Mesalazine—Crohn's disease	0.00222	0.0028	CcSEcCtD
Naltrexone—Muscle spasms—Mesalazine—Crohn's disease	0.00221	0.00278	CcSEcCtD
Naltrexone—Vomiting—Mercaptopurine—Crohn's disease	0.0022	0.00277	CcSEcCtD
Naltrexone—Rash—Mercaptopurine—Crohn's disease	0.00218	0.00274	CcSEcCtD
Naltrexone—Dermatitis—Mercaptopurine—Crohn's disease	0.00218	0.00274	CcSEcCtD
Naltrexone—Vision blurred—Mesalazine—Crohn's disease	0.00217	0.00273	CcSEcCtD
Naltrexone—Tremor—Mesalazine—Crohn's disease	0.00215	0.00271	CcSEcCtD
Naltrexone—Increased appetite—Prednisone—Crohn's disease	0.00215	0.00271	CcSEcCtD
Naltrexone—Myalgia—Azathioprine—Crohn's disease	0.00215	0.00271	CcSEcCtD
Naltrexone—Arthralgia—Azathioprine—Crohn's disease	0.00215	0.00271	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00213	0.00269	CcSEcCtD
Naltrexone—Ill-defined disorder—Mesalazine—Crohn's disease	0.00213	0.00269	CcSEcCtD
Naltrexone—Discomfort—Azathioprine—Crohn's disease	0.00212	0.00267	CcSEcCtD
Naltrexone—Angioedema—Mesalazine—Crohn's disease	0.0021	0.00265	CcSEcCtD
Naltrexone—Purpura—Prednisone—Crohn's disease	0.0021	0.00264	CcSEcCtD
Naltrexone—Malaise—Mesalazine—Crohn's disease	0.00207	0.00261	CcSEcCtD
Naltrexone—Syncope—Mesalazine—Crohn's disease	0.00206	0.0026	CcSEcCtD
Naltrexone—Lethargy—Prednisone—Crohn's disease	0.00206	0.0026	CcSEcCtD
Naltrexone—Nausea—Mercaptopurine—Crohn's disease	0.00205	0.00259	CcSEcCtD
Naltrexone—Infection—Azathioprine—Crohn's disease	0.00205	0.00258	CcSEcCtD
Naltrexone—Palpitations—Mesalazine—Crohn's disease	0.00203	0.00256	CcSEcCtD
Naltrexone—Loss of consciousness—Mesalazine—Crohn's disease	0.00202	0.00254	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00202	0.00254	CcSEcCtD
Naltrexone—Cough—Mesalazine—Crohn's disease	0.00201	0.00253	CcSEcCtD
Naltrexone—Skin disorder—Azathioprine—Crohn's disease	0.002	0.00252	CcSEcCtD
Naltrexone—Hypertension—Mesalazine—Crohn's disease	0.00198	0.0025	CcSEcCtD
Naltrexone—Psychotic disorder—Prednisone—Crohn's disease	0.00197	0.00248	CcSEcCtD
Naltrexone—Arthralgia—Mesalazine—Crohn's disease	0.00196	0.00246	CcSEcCtD
Naltrexone—Chest pain—Mesalazine—Crohn's disease	0.00196	0.00246	CcSEcCtD
Naltrexone—Myalgia—Mesalazine—Crohn's disease	0.00196	0.00246	CcSEcCtD
Naltrexone—Anxiety—Mesalazine—Crohn's disease	0.00195	0.00246	CcSEcCtD
Naltrexone—Face oedema—Prednisone—Crohn's disease	0.00195	0.00246	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00194	0.00245	CcSEcCtD
Naltrexone—Discomfort—Mesalazine—Crohn's disease	0.00193	0.00244	CcSEcCtD
Naltrexone—Irritability—Prednisone—Crohn's disease	0.00193	0.00243	CcSEcCtD
Naltrexone—Dry mouth—Mesalazine—Crohn's disease	0.00191	0.00241	CcSEcCtD
Naltrexone—Confusional state—Mesalazine—Crohn's disease	0.00189	0.00238	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00188	0.0102	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00188	0.00236	CcSEcCtD
Naltrexone—Anaphylactic shock—Mesalazine—Crohn's disease	0.00188	0.00236	CcSEcCtD
Naltrexone—Oedema—Mesalazine—Crohn's disease	0.00188	0.00236	CcSEcCtD
Naltrexone—Infection—Mesalazine—Crohn's disease	0.00186	0.00235	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00185	0.0101	CbGpPWpGaD
Naltrexone—Shock—Mesalazine—Crohn's disease	0.00185	0.00232	CcSEcCtD
Naltrexone—Nervous system disorder—Mesalazine—Crohn's disease	0.00184	0.00232	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00184	0.00998	CbGpPWpGaD
Naltrexone—Tachycardia—Mesalazine—Crohn's disease	0.00183	0.00231	CcSEcCtD
Naltrexone—Skin disorder—Mesalazine—Crohn's disease	0.00182	0.0023	CcSEcCtD
Naltrexone—Hyperhidrosis—Mesalazine—Crohn's disease	0.00181	0.00228	CcSEcCtD
Naltrexone—Anorexia—Mesalazine—Crohn's disease	0.00179	0.00225	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00178	0.00224	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00178	0.00966	CbGpPWpGaD
Naltrexone—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00178	0.00224	CcSEcCtD
Naltrexone—OPRD1—G alpha (i) signalling events—CCR9—Crohn's disease	0.00177	0.0096	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00171	0.00215	CcSEcCtD
Naltrexone—Sweating increased—Prednisone—Crohn's disease	0.0017	0.00214	CcSEcCtD
Naltrexone—Feeling abnormal—Azathioprine—Crohn's disease	0.0017	0.00214	CcSEcCtD
Naltrexone—Insomnia—Mesalazine—Crohn's disease	0.0017	0.00214	CcSEcCtD
Naltrexone—Paraesthesia—Mesalazine—Crohn's disease	0.00168	0.00212	CcSEcCtD
Naltrexone—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00168	0.00212	CcSEcCtD
Naltrexone—Dyspnoea—Mesalazine—Crohn's disease	0.00167	0.00211	CcSEcCtD
Naltrexone—Somnolence—Mesalazine—Crohn's disease	0.00167	0.0021	CcSEcCtD
Naltrexone—OPRM1—IL4-mediated signaling events—SOCS1—Crohn's disease	0.00166	0.00899	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00164	0.00891	CbGpPWpGaD
Naltrexone—Decreased appetite—Mesalazine—Crohn's disease	0.00163	0.00205	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—ACKR2—Crohn's disease	0.00163	0.00885	CbGpPWpGaD
Naltrexone—Body temperature increased—Azathioprine—Crohn's disease	0.00163	0.00205	CcSEcCtD
Naltrexone—Abdominal pain—Azathioprine—Crohn's disease	0.00163	0.00205	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL17A—Crohn's disease	0.00162	0.00881	CbGpPWpGaD
Naltrexone—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00162	0.00204	CcSEcCtD
Naltrexone—Fatigue—Mesalazine—Crohn's disease	0.00162	0.00204	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—LRRK2—Crohn's disease	0.00161	0.00873	CbGpPWpGaD
Naltrexone—Pain—Mesalazine—Crohn's disease	0.0016	0.00202	CcSEcCtD
Naltrexone—Constipation—Mesalazine—Crohn's disease	0.0016	0.00202	CcSEcCtD
Naltrexone—Weight increased—Prednisone—Crohn's disease	0.00159	0.002	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00159	0.00861	CbGpPWpGaD
Naltrexone—Weight decreased—Prednisone—Crohn's disease	0.00158	0.00199	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00155	0.00844	CbGpPWpGaD
Naltrexone—Depression—Prednisone—Crohn's disease	0.00155	0.00195	CcSEcCtD
Naltrexone—OPRK1—G alpha (i) signalling events—CCR9—Crohn's disease	0.00155	0.00842	CbGpPWpGaD
Naltrexone—Feeling abnormal—Mesalazine—Crohn's disease	0.00155	0.00195	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—MLN—Crohn's disease	0.00155	0.00839	CbGpPWpGaD
Naltrexone—Acute coronary syndrome—Prednisone—Crohn's disease	0.00153	0.00193	CcSEcCtD
Naltrexone—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00153	0.00193	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00153	0.00828	CbGpPWpGaD
Naltrexone—Myocardial infarction—Prednisone—Crohn's disease	0.00153	0.00192	CcSEcCtD
Naltrexone—Hypersensitivity—Azathioprine—Crohn's disease	0.00152	0.00191	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.0015	0.00816	CbGpPWpGaD
Naltrexone—Urticaria—Mesalazine—Crohn's disease	0.00149	0.00188	CcSEcCtD
Naltrexone—OPRM1—IL4-mediated signaling events—IL10—Crohn's disease	0.00149	0.00807	CbGpPWpGaD
Naltrexone—Body temperature increased—Mesalazine—Crohn's disease	0.00148	0.00187	CcSEcCtD
Naltrexone—Abdominal pain—Mesalazine—Crohn's disease	0.00148	0.00187	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00144	0.00781	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—RIPK2—Crohn's disease	0.00144	0.00781	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ACKR2—Crohn's disease	0.00143	0.00776	CbGpPWpGaD
Naltrexone—Diarrhoea—Azathioprine—Crohn's disease	0.00141	0.00177	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00141	0.00763	CbGpPWpGaD
Naltrexone—Hallucination—Prednisone—Crohn's disease	0.00139	0.00175	CcSEcCtD
Naltrexone—UGT1A1—Metapathway biotransformation—GPX4—Crohn's disease	0.00139	0.00754	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00139	0.00754	CbGpPWpGaD
Naltrexone—Hypersensitivity—Mesalazine—Crohn's disease	0.00138	0.00174	CcSEcCtD
Naltrexone—Connective tissue disorder—Prednisone—Crohn's disease	0.00137	0.00173	CcSEcCtD
Naltrexone—Dizziness—Azathioprine—Crohn's disease	0.00136	0.00172	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—MLN—Crohn's disease	0.00136	0.00736	CbGpPWpGaD
Naltrexone—Asthenia—Mesalazine—Crohn's disease	0.00135	0.0017	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00134	0.00726	CbGpPWpGaD
Naltrexone—Pruritus—Mesalazine—Crohn's disease	0.00133	0.00167	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—CCR9—Crohn's disease	0.00131	0.00712	CbGpPWpGaD
Naltrexone—Vomiting—Azathioprine—Crohn's disease	0.00131	0.00165	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00131	0.0071	CbGpPWpGaD
Naltrexone—Eye disorder—Prednisone—Crohn's disease	0.00131	0.00164	CcSEcCtD
Naltrexone—Rash—Azathioprine—Crohn's disease	0.0013	0.00164	CcSEcCtD
Naltrexone—Dermatitis—Azathioprine—Crohn's disease	0.0013	0.00163	CcSEcCtD
Naltrexone—Headache—Azathioprine—Crohn's disease	0.00129	0.00163	CcSEcCtD
Naltrexone—Diarrhoea—Mesalazine—Crohn's disease	0.00128	0.00162	CcSEcCtD
Naltrexone—Angiopathy—Prednisone—Crohn's disease	0.00127	0.0016	CcSEcCtD
Naltrexone—Immune system disorder—Prednisone—Crohn's disease	0.00126	0.00159	CcSEcCtD
Naltrexone—Dizziness—Mesalazine—Crohn's disease	0.00124	0.00156	CcSEcCtD
Naltrexone—Alopecia—Prednisone—Crohn's disease	0.00123	0.00155	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00123	0.00669	CbGpPWpGaD
Naltrexone—Mental disorder—Prednisone—Crohn's disease	0.00122	0.00154	CcSEcCtD
Naltrexone—Nausea—Azathioprine—Crohn's disease	0.00122	0.00154	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00122	0.00661	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00122	0.0066	CbGpPWpGaD
Naltrexone—Malnutrition—Prednisone—Crohn's disease	0.00122	0.00153	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—ACKR2—Crohn's disease	0.00121	0.00656	CbGpPWpGaD
Naltrexone—Vomiting—Mesalazine—Crohn's disease	0.00119	0.0015	CcSEcCtD
Naltrexone—Rash—Mesalazine—Crohn's disease	0.00118	0.00149	CcSEcCtD
Naltrexone—Dermatitis—Mesalazine—Crohn's disease	0.00118	0.00149	CcSEcCtD
Naltrexone—Headache—Mesalazine—Crohn's disease	0.00118	0.00148	CcSEcCtD
Naltrexone—OPRD1—G alpha (i) signalling events—CCR6—Crohn's disease	0.00117	0.00636	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00115	0.00622	CbGpPWpGaD
Naltrexone—Vision blurred—Prednisone—Crohn's disease	0.00115	0.00144	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—MLN—Crohn's disease	0.00115	0.00622	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.00114	0.00616	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00113	0.00614	CbGpPWpGaD
Naltrexone—Ill-defined disorder—Prednisone—Crohn's disease	0.00113	0.00142	CcSEcCtD
Naltrexone—Agitation—Prednisone—Crohn's disease	0.00112	0.00141	CcSEcCtD
Naltrexone—Nausea—Mesalazine—Crohn's disease	0.00111	0.0014	CcSEcCtD
Naltrexone—Angioedema—Prednisone—Crohn's disease	0.00111	0.0014	CcSEcCtD
Naltrexone—Malaise—Prednisone—Crohn's disease	0.0011	0.00138	CcSEcCtD
Naltrexone—Syncope—Prednisone—Crohn's disease	0.00109	0.00137	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00109	0.0059	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCR9—Crohn's disease	0.00107	0.00581	CbGpPWpGaD
Naltrexone—Loss of consciousness—Prednisone—Crohn's disease	0.00107	0.00135	CcSEcCtD
Naltrexone—Convulsion—Prednisone—Crohn's disease	0.00105	0.00133	CcSEcCtD
Naltrexone—Hypertension—Prednisone—Crohn's disease	0.00105	0.00132	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00104	0.00566	CbGpPWpGaD
Naltrexone—Arthralgia—Prednisone—Crohn's disease	0.00104	0.0013	CcSEcCtD
Naltrexone—Myalgia—Prednisone—Crohn's disease	0.00104	0.0013	CcSEcCtD
Naltrexone—Anxiety—Prednisone—Crohn's disease	0.00103	0.0013	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00103	0.00559	CbGpPWpGaD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00103	0.0013	CcSEcCtD
Naltrexone—OPRK1—G alpha (i) signalling events—CCR6—Crohn's disease	0.00103	0.00558	CbGpPWpGaD
Naltrexone—Discomfort—Prednisone—Crohn's disease	0.00102	0.00129	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.00101	0.00549	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—GPR65—Crohn's disease	0.000996	0.00541	CbGpPWpGaD
Naltrexone—Anaphylactic shock—Prednisone—Crohn's disease	0.000993	0.00125	CcSEcCtD
Naltrexone—Oedema—Prednisone—Crohn's disease	0.000993	0.00125	CcSEcCtD
Naltrexone—Infection—Prednisone—Crohn's disease	0.000986	0.00124	CcSEcCtD
Naltrexone—Shock—Prednisone—Crohn's disease	0.000977	0.00123	CcSEcCtD
Naltrexone—Nervous system disorder—Prednisone—Crohn's disease	0.000974	0.00123	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000969	0.00526	CbGpPWpGaD
Naltrexone—Tachycardia—Prednisone—Crohn's disease	0.000969	0.00122	CcSEcCtD
Naltrexone—Skin disorder—Prednisone—Crohn's disease	0.000964	0.00121	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—Crohn's disease	0.00096	0.00121	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000958	0.0052	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000954	0.00518	CbGpPWpGaD
Naltrexone—Anorexia—Prednisone—Crohn's disease	0.000946	0.00119	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CCR9—Crohn's disease	0.000939	0.0051	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000932	0.00506	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000904	0.00114	CcSEcCtD
Naltrexone—Insomnia—Prednisone—Crohn's disease	0.000898	0.00113	CcSEcCtD
Naltrexone—Paraesthesia—Prednisone—Crohn's disease	0.000891	0.00112	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000891	0.00483	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—JAK2—Crohn's disease	0.000891	0.00483	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—MLN—Crohn's disease	0.000873	0.00474	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—GPR65—Crohn's disease	0.000873	0.00474	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCR6—Crohn's disease	0.000869	0.00471	CbGpPWpGaD
Naltrexone—Decreased appetite—Prednisone—Crohn's disease	0.000863	0.00109	CcSEcCtD
Naltrexone—Fatigue—Prednisone—Crohn's disease	0.000856	0.00108	CcSEcCtD
Naltrexone—Constipation—Prednisone—Crohn's disease	0.000849	0.00107	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—IL17A—Crohn's disease	0.000845	0.00459	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00084	0.00456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ACKR2—Crohn's disease	0.000837	0.00454	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000821	0.00445	CbGpPWpGaD
Naltrexone—Feeling abnormal—Prednisone—Crohn's disease	0.000818	0.00103	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000817	0.00443	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Prednisone—Crohn's disease	0.000812	0.00102	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000806	0.00437	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR9—Crohn's disease	0.000794	0.00431	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MLN—Crohn's disease	0.000793	0.0043	CbGpPWpGaD
Naltrexone—Urticaria—Prednisone—Crohn's disease	0.000789	0.000993	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—IL12B—Crohn's disease	0.000786	0.00426	CbGpPWpGaD
Naltrexone—Body temperature increased—Prednisone—Crohn's disease	0.000785	0.000988	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—Crohn's disease	0.000785	0.000988	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—MLN—Crohn's disease	0.000766	0.00416	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GPR65—Crohn's disease	0.000738	0.00401	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.000735	0.00399	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ACKR2—Crohn's disease	0.000734	0.00398	CbGpPWpGaD
Naltrexone—Hypersensitivity—Prednisone—Crohn's disease	0.000731	0.000921	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000719	0.0039	CbGpPWpGaD
Naltrexone—Asthenia—Prednisone—Crohn's disease	0.000712	0.000897	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00071	0.00385	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCR6—Crohn's disease	0.00071	0.00385	CbGpPWpGaD
Naltrexone—Pruritus—Prednisone—Crohn's disease	0.000702	0.000884	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—MLN—Crohn's disease	0.000696	0.00377	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000691	0.00375	CbGpPWpGaD
Naltrexone—Diarrhoea—Prednisone—Crohn's disease	0.000679	0.000855	CcSEcCtD
Naltrexone—Dizziness—Prednisone—Crohn's disease	0.000656	0.000827	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—MLN—Crohn's disease	0.000647	0.00351	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.000639	0.00347	CbGpPWpGaD
Naltrexone—Vomiting—Prednisone—Crohn's disease	0.000631	0.000795	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—CD4—Crohn's disease	0.000627	0.0034	CbGpPWpGaD
Naltrexone—Rash—Prednisone—Crohn's disease	0.000626	0.000788	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—Crohn's disease	0.000625	0.000787	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—PTGER4—Crohn's disease	0.000625	0.00339	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCR6—Crohn's disease	0.000622	0.00338	CbGpPWpGaD
Naltrexone—Headache—Prednisone—Crohn's disease	0.000622	0.000783	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—ACKR2—Crohn's disease	0.00062	0.00337	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000608	0.0033	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR9—Crohn's disease	0.000605	0.00329	CbGpPWpGaD
Naltrexone—Nausea—Prednisone—Crohn's disease	0.00059	0.000743	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—MLN—Crohn's disease	0.000588	0.00319	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL1B—Crohn's disease	0.000579	0.00314	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL10—Crohn's disease	0.000574	0.00312	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GPR65—Crohn's disease	0.000563	0.00305	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR9—Crohn's disease	0.00055	0.00298	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—PTGER4—Crohn's disease	0.000548	0.00297	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR9—Crohn's disease	0.000531	0.00288	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR6—Crohn's disease	0.000526	0.00285	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2RA—Crohn's disease	0.000512	0.00278	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GPR65—Crohn's disease	0.000511	0.00277	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ACKR2—Crohn's disease	0.000494	0.00268	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GPR65—Crohn's disease	0.000494	0.00268	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR9—Crohn's disease	0.000482	0.00262	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MLN—Crohn's disease	0.000469	0.00254	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—PTGER4—Crohn's disease	0.000463	0.00251	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR9—Crohn's disease	0.000449	0.00243	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GPR65—Crohn's disease	0.000448	0.00243	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000448	0.00243	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ACKR2—Crohn's disease	0.000433	0.00235	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TAGAP—Crohn's disease	0.000429	0.00233	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GPR65—Crohn's disease	0.000417	0.00226	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MLN—Crohn's disease	0.000411	0.00223	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR9—Crohn's disease	0.000407	0.00221	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR6—Crohn's disease	0.000401	0.00218	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000393	0.00213	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PLA2G4F—Crohn's disease	0.000388	0.00211	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GPR65—Crohn's disease	0.000379	0.00206	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000378	0.00205	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TAGAP—Crohn's disease	0.000376	0.00204	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RSPO3—Crohn's disease	0.000375	0.00203	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ACKR2—Crohn's disease	0.000366	0.00199	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR6—Crohn's disease	0.000364	0.00198	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000361	0.00196	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SEL1L—Crohn's disease	0.000355	0.00193	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000353	0.00192	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR6—Crohn's disease	0.000352	0.00191	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MLN—Crohn's disease	0.000347	0.00188	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—Crohn's disease	0.000339	0.00184	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IFNG—Crohn's disease	0.000338	0.00183	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000332	0.0018	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000331	0.0018	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTMR3—Crohn's disease	0.00033	0.00179	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RSPO3—Crohn's disease	0.000328	0.00178	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR9—Crohn's disease	0.000325	0.00176	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000323	0.00176	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000323	0.00176	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PTGER4—Crohn's disease	0.000321	0.00174	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR6—Crohn's disease	0.000319	0.00173	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TAGAP—Crohn's disease	0.000318	0.00172	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	0.000314	0.0017	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SEL1L—Crohn's disease	0.000311	0.00169	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PTGER4—Crohn's disease	0.00031	0.00168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GPR65—Crohn's disease	0.000302	0.00164	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL1B—Crohn's disease	0.000301	0.00164	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL3—Crohn's disease	0.000301	0.00163	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.0003	0.00163	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR6—Crohn's disease	0.000297	0.00161	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000291	0.00158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR9—Crohn's disease	0.000285	0.00155	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTGER4—Crohn's disease	0.000281	0.00153	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL8—Crohn's disease	0.00028	0.00152	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RSPO3—Crohn's disease	0.000278	0.00151	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL3—Crohn's disease	0.000273	0.00148	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR6—Crohn's disease	0.00027	0.00146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GPR65—Crohn's disease	0.000265	0.00144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000264	0.00143	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL3—Crohn's disease	0.000264	0.00143	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000263	0.00143	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SEL1L—Crohn's disease	0.000263	0.00143	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000262	0.00142	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—FADS1—Crohn's disease	0.000257	0.0014	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000255	0.00138	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX4—Crohn's disease	0.000241	0.00131	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR9—Crohn's disease	0.000241	0.00131	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL3—Crohn's disease	0.000239	0.0013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTGER4—Crohn's disease	0.000238	0.00129	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GCKR—Crohn's disease	0.000233	0.00126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000232	0.00126	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL8—Crohn's disease	0.000229	0.00124	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000228	0.00124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GPR65—Crohn's disease	0.000224	0.00121	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL3—Crohn's disease	0.000223	0.00121	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000223	0.00121	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—Crohn's disease	0.000219	0.00119	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000216	0.00117	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR6—Crohn's disease	0.000215	0.00117	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000211	0.00114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL3—Crohn's disease	0.000202	0.0011	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000201	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL8—Crohn's disease	0.000201	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000196	0.00106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RBX1—Crohn's disease	0.000195	0.00106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2RA—Crohn's disease	0.000191	0.00104	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTGER4—Crohn's disease	0.000189	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR6—Crohn's disease	0.000189	0.00102	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000185	0.001	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G4F—Crohn's disease	0.000178	0.000967	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RBX1—Crohn's disease	0.000171	0.000926	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—UBE2D1—Crohn's disease	0.000171	0.000926	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—Crohn's disease	0.000169	0.00092	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2RA—Crohn's disease	0.000168	0.00091	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTGER4—Crohn's disease	0.000166	0.000901	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RIPK2—Crohn's disease	0.000165	0.000898	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL3—Crohn's disease	0.000161	0.000876	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.00016	0.000867	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR6—Crohn's disease	0.000159	0.000865	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000156	0.000847	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RASGRP1—Crohn's disease	0.000156	0.000847	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTMR3—Crohn's disease	0.000152	0.000822	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—UBE2D1—Crohn's disease	0.00015	0.000812	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RIPK2—Crohn's disease	0.000145	0.000787	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RBX1—Crohn's disease	0.000144	0.000783	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2RA—Crohn's disease	0.000142	0.000769	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—JAK2—Crohn's disease	0.000142	0.000768	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL3—Crohn's disease	0.000141	0.000768	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SOCS1—Crohn's disease	0.000141	0.000767	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTGER4—Crohn's disease	0.00014	0.000762	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RASGRP1—Crohn's disease	0.000137	0.000743	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—TYK2—Crohn's disease	0.000135	0.000731	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000129	0.000701	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—JAK2—Crohn's disease	0.000129	0.000698	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—UBE2D1—Crohn's disease	0.000126	0.000686	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—JAK2—Crohn's disease	0.000124	0.000674	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SOCS1—Crohn's disease	0.000124	0.000673	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RIPK2—Crohn's disease	0.000123	0.000665	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMAD3—Crohn's disease	0.000122	0.000662	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL3—Crohn's disease	0.00012	0.000649	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—TYK2—Crohn's disease	0.000118	0.000641	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FADS1—Crohn's disease	0.000118	0.000641	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—Crohn's disease	0.000117	0.000637	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RASGRP1—Crohn's disease	0.000116	0.000628	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000113	0.000615	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2RA—Crohn's disease	0.000113	0.000613	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—JAK2—Crohn's disease	0.000113	0.000612	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX4—Crohn's disease	0.000111	0.0006	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	0.000108	0.000586	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMAD3—Crohn's disease	0.000107	0.000581	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCKR—Crohn's disease	0.000107	0.000579	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—JAK2—Crohn's disease	0.000105	0.000569	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS1—Crohn's disease	0.000105	0.000569	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—Crohn's disease	0.000103	0.000558	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—TYK2—Crohn's disease	9.99e-05	0.000542	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2RA—Crohn's disease	9.91e-05	0.000538	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—Crohn's disease	9.58e-05	0.00052	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—JAK2—Crohn's disease	9.53e-05	0.000517	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMAD3—Crohn's disease	9.05e-05	0.000491	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—Crohn's disease	8.7e-05	0.000472	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2RA—Crohn's disease	8.38e-05	0.000455	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TYK2—Crohn's disease	7.96e-05	0.000432	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAK2—Crohn's disease	7.6e-05	0.000412	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—Crohn's disease	7.41e-05	0.000402	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	7.25e-05	0.000394	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TYK2—Crohn's disease	6.98e-05	0.000379	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—Crohn's disease	6.93e-05	0.000376	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAK2—Crohn's disease	6.66e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—Crohn's disease	6.59e-05	0.000358	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—Crohn's disease	6.48e-05	0.000352	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—Crohn's disease	6.08e-05	0.00033	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TYK2—Crohn's disease	5.9e-05	0.00032	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—Crohn's disease	5.78e-05	0.000314	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAK2—Crohn's disease	5.63e-05	0.000306	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—Crohn's disease	5.58e-05	0.000303	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—Crohn's disease	5.14e-05	0.000279	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—Crohn's disease	4.89e-05	0.000265	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—Crohn's disease	4.89e-05	0.000265	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—Crohn's disease	4.13e-05	0.000224	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—Crohn's disease	3.89e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—Crohn's disease	3.42e-05	0.000185	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—Crohn's disease	3.4e-05	0.000184	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—Crohn's disease	2.97e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—Crohn's disease	2.89e-05	0.000157	CbGpPWpGaD
